An example of this is in prostate cancer where EZH2 acted as a co-activator for transcription factors independent of the PRC2 complex.53 In addition, other studies have suggested that elevated expression of EZH2 at diagnosis may be associated with a better prognosis.54 This would not appear to be the case in myeloma, where we have shown high EZH2 expression to be associated with features of aggressive disease, for example, increased proliferation rate and high GEP70 score. The gene discussed is EZH2; the disease is plasma cell myeloma.